Search results
Drug targeting clear cell renal cell carcinoma shows promising approach
Newswise· 3 days agoApril 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 11 hours agoOutside the U.S., KEYTRUDA growth was driven by continued uptake in earlier-stage cancers, including high-risk, early stage, triple-negative breast...
Moriah Elyse Kerns - Valencia County News-Bulletin
Valencia County News-Bulletin· 19 hours agoMoriah Elyse Kerns, age 27, a resident of Los Lunas, passed away on April 20, 2024, as a result of renal cell carcinoma. Moriah was pursuing ...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 15 hours agoKeytruda, the biggest product in Merck’s portfolio, generated sales of $6.95 billion in the quarter,...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 1 day agoPatients will receive Keytruda or Keytruda plus the vaccine after bladder or kidney removal. Bladder...
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 14 hours agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
KSAN - KLST San Angelo· 1 day agoFirst-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study. First-in-class PD-1/IL-2 bispecific ...
Merck beats earnings forecasts as cancer drug sales boom
Crain's New York Business· 14 hours agoThe guidance comes as Merck’s first-quarter earnings topped $15.8 billion, a 9% increase from the...
Cancer drug trial provides lessons for future
Medical Xpress· 14 hours agoA cancer drug was found to be ineffective in preventing recurrence of kidney cancer in patients who recently underwent tumor removal surgery, according to a clinical trial published in the Journal ...
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 1 day agoShanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...